Treatment persistence and adherence in people with type 2 diabetes switching to iGlarLixi vs free-dose combinations of basal insulin and glucagon-like peptide 1 receptor agonist - Edelman, S; Cassarino, D; Kayne, D (J Manag Care Spec Pharm, 2022)
et al.